Form 4: Fulgent Genetics Director Receives Equity Grant

Director Linda Dong was granted 11,117 restricted stock units in Fulgent Genetics, Inc. as part of an equity compensation plan.

Summary

• Director Linda Dong acquired 11,117 shares of common stock in the form of restricted stock units (RSUs).
• The transaction occurred on May 14, 2026.
• Following this transaction, the reporting person holds a total of 38,758 shares of common stock.
• The RSUs vest over a four-year period, with 25% vesting after 12 months and the remainder vesting quarterly over the following 36 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to continued service to the issuer, creating a dependency on the director's ongoing tenure.

Future Outlook

The equity grant is subject to a four-year vesting schedule, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and strategic alignment within the biotechnology and diagnostics sector.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard equity compensation practices for board members in the U.S. healthcare and diagnostics industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation practices.

Next Steps

• Vesting of 1/4th of the shares on May 14, 2027.
• Quarterly vesting of 1/16th of the shares thereafter.

Key Dates

Keywords

Fulgent Genetics, FLGT, Director, Equity Grant, Insider Ownership, Restricted Stock Units